Evaluating the Role of Biomarkers for Evaluating Treatment Response & Disease Progression in Neuroinflammatory Disorders

Time: 9:30 am
day: Conference Day Two


  • Dissecting biomarkers of acute inflammatory versus chronic insidious injury in Multiple Sclerosis
  • Evaluating the direct and indirect impacts of a high-efficacy disease modifying treatment
  • Identifying proof-of-activity biomarkers correlating with clinical outcomes and their implications for drug development